Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 06 2024 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 6, 2024
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Novo Nordisk A/S purchases B shares worth DKK 5,428
million from Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk
A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings
A/S. The transaction is part of Novo Nordisk A/S’ 2024 share repurchase programme of up to a total of DKK 20 billion to be executed
during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day
volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S’
quarterly financial results.
Prior to the sale of B shares, Novo Holdings A/S’ ownership of
Novo Nordisk A/S was 28.3% of the share capital and 77.4% of the votes. Following the transaction, Novo Holdings A/S owns 1,074,872,000
A shares of DKK 0.10 and 183,871,750 B shares of DKK 0.10, corresponding to 28.2% of the capital and 77.3% of the votes in Novo Nordisk
A/S.
The transaction is in line with the announcement on 31 January 2024 that
Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s incentive programmes
have resulted in a net transfer from Novo Nordisk of 93,461 B shares in the period from 2 May 2024 to 6 May 2024.
With the transactions stated above, Novo Nordisk A/S owns a total of
10,163,508 B shares of DKK 0.10, corresponding to 0.2% of the share capital, as treasury shares. The total number of A and B shares in
the company is 4,465,000,000 of DKK 0.10 including treasury shares.
Novo
Nordisk A/S Investor
Relations | Novo
Allé 1 2880
Bagsværd Denmark | Telephone: +45
4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | Company
announcement No 37 / 2024 |
Novo Nordisk is a leading global healthcare company, founded in 1923
and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
|
|
Ida Melvold Gjøsund
+45 3077 5649
idmg@novonordisk.com |
|
Novo
Nordisk A/S Investor
Relations | Novo
Allé 1 2880
Bagsværd Denmark | Telephone: +45
4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | Company
announcement No 37 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 6, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Oct 2023 to Oct 2024